WEREWOLF THERAPEUTICS, INC. Increase (Decrease) in Derivative Liabilities
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Increase (Decrease) in Derivative Liabilities of -$1.03 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2023-11-14
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2023-09-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2023-06-30 was -$9.00K, a 103.44% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2023-03-31 was -$1.02M.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2022-09-30 was -$9.00K.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month |
|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$9.00K derived: sum of 2 quarters · filed 2023-11-14 | -$1.03M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.03M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$1.02M 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $253.00K derived: sum of 2 quarters · filed 2023-11-14 | $253.00K 10-Q · filed 2023-11-14 |
| 2022-06-30 | $262.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $262.00K 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |